Kronbichler A, Leierer J, Shin JI, et al. - Researchers performed determination of the frequency of venous thromboembolism (VTE) events in the Rituximab Antineutrophil Cytoplasmic Antibody (ANCA)–Associated Vasculitis (RAVE) trial. In addition, they sought novel potential risk factors. Among 197 patients enrolled in the RAVE trial, 16 patients (8.1%) had VTE occurrence with an overall average time to event of 1.5 months (range 1.0–2.75). They observed an increased risk to develop VTE among patients diagnosed as having ANCA-associated vasculitis with pulmonary hemorrhage, positive proteinase 3-ANCA, heart involvement, and the presence of red blood cell casts.